Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072028 | 0.83 | DRD3 (0.46) | DRD2DRD3ADORA2AKDM4EALDH1A1 | |
| SCHEMBL6071513 | 0.79 | ACHE (0.45) | ACHEBCHEKDM4EALDH1A1MAPK1 | |
| SCHEMBL6071957 | 0.76 | NSD2 (0.51) | ACHEBCHEKDM4EALDH1A1RAD52 | |
| SCHEMBL30624981 | 0.72 | ADORA2A (0.43) | DRD2DRD3ADORA2AKDM4EDRD1 | |
| SCHEMBL10644222 | 0.67 | DRD2 (0.76) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12125697 | 0.67 | DRD2 (0.76) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12125694 | 0.67 | DRD2 (0.76) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL28887837 | 0.66 | ACHE (0.49) | ACHEBCHEKDM4EALDH1A1RAD52 | |
| SCHEMBL28398796 | 0.66 | ACHE (0.49) | ACHEBCHEKDM4EALDH1A1RAD52 | |
| SCHEMBL6252164 | 0.65 | KDM4E (0.60) | ADORA2AACHEKDM4EALDH1A1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | DRD2 4427/4885DRD3 4452/4885ADORA2A 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.